Prestige Consumer Healthcare Q2 rev $286.3M, EPS $1.07, leverage down to 3.0x

Prestige Consumer Healthcare Inc.

2024-Q2 EPS reported $2.13 revenue$565,625,000

Q2 FY2024 revenue $286.3M, slightly below prior-year record of $289.3M but ahead of internal outlook.
Diluted EPS $1.07 vs $1.02 YoY, up 5.4%; net income $53.6M vs $51.0M.
North American OTC revenue fell 3% to $244.4M; International OTC rose ~12.6% to $41.9M.
Non-GAAP free cash flow $59.5M, up from $55.2M; covenant leverage ratio improved to 3.0x.
FY2024 outlook reaffirmed: rev $1,135-1,140M, diluted EPS $4.27-4.32, FCF $240M+.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Prestige Consumer Healthcare Inc. reported the fiscal quarter ended September 30, 2023 results: revenue $286.3 million, net income $53.6 million, EPS $1.07. Guidance reaffirmed.

Period: the fiscal quarter ended September 30, 2023
Revenue: $286.3 million
Net income: $53.6 million
EPS: $1.07
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Reported revenues in the second quarter of fiscal 2024 of $286.3 million compared to a record $289.3 million in the second quarter of fiscal 2023. Revenues decreased 0.7% versus the prior year second quarter excluding the impact of foreign currency. The revenue performance for the quarter was led by Cough & Cold and Ear & Eye Care category performances in North America and strong International OTC segment growth versus the prior year comparable period, offset by declines in certain other categories and the planned strategic exit of private label revenues. Reported net income for the second quarter of fiscal 2024 totaled $53.6 million, compared to the prior year second quarter’s net income of $51.0 million. Diluted earnings per share of $1.07 for the second quarter of fiscal 2024 increased 5.4% versus $1.02 in the prior year comparable period.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Prestige Consumer Healthcare Inc. reported the six months ended September 30, 2023 results: revenue $565.6 million, net income $106.8 million, EPS $2.13. Guidance reaffirmed.

Period: the six months ended September 30, 2023
Revenue: $565.6 million
Net income: $106.8 million
EPS: $2.13
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Reported revenues for the first six months of fiscal 2024 totaled $565.6 million and compared to revenues of $566.3 million for the first six months of fiscal 2023. Revenues increased 0.5% versus the prior year six-month period, excluding the impact of foreign currency. The revenue growth for the first six months was driven by International OTC segment performance and strong Dermatological category sales in North America, offset by lower Women’s Health category sales and the strategic exit of private label revenues. Reported net income for the first six months of fiscal 2024 totaled $106.8 million versus the prior year comparable period net income of $106.3 million. Diluted earnings per share were $2.13 for the first six months of fiscal 2024 increased compared to diluted earnings per share of $2.11 in the prior year comparable period.

View on SEC.gov

Browse all earnings releases →

Prestige Consumer Healthcare Inc. filing history →

Source: SEC EDGAR

accession 0001295947-23-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.